作者
Madalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, Kathy Fu, Geneviève Laroche, Zaid Taha, Demi van Der Horst, Lena Cassin, Renée M Van Der Sluis, Enrico Palermo, Daniele Di Carlo, David Jacobs, Glib Maznyi, Taha Azad, Ragunath Singaravelu, Fanghui Ren, Anne Louise Hansen, Manja Idorn, Christian K Holm, Martin R Jakobsen, Julien Van Grevenynghe, John Hiscott, Søren R Paludan, John C Bell, Jean Seguin, Luc A Sabourin, Marceline Côté, Jean-Simon Diallo, Tommy Alain, David Olagnier
发表日期
2021/10/18
期刊
ACS infectious diseases
卷号
7
期号
11
页码范围
3034-3051
出版商
American Chemical Society
简介
The antimicrobial medication malarone (atovaquone/proguanil) is used as a fixed-dose combination for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers. It is an inexpensive, efficacious, and safe drug frequently prescribed around the world. Following anecdotal evidence from 17 patients in the provinces of Quebec and Ontario, Canada, suggesting that malarone/atovaquone may present some benefits in protecting against COVID-19, we sought to examine its antiviral potential in limiting the replication of SARS-CoV-2 in cellular models of infection. In VeroE6 expressing human TMPRSS2 and human lung Calu-3 epithelial cells, we show that the active compound atovaquone at micromolar concentrations potently inhibits the replication of SARS-CoV-2 and other variants of concern including the alpha, beta, and delta variants. Importantly, atovaquone …
学术搜索中的文章
ME Carter-Timofte, R Arulanandam, N Kurmasheva… - ACS infectious diseases, 2021